

MINUTES OF THE 270th MEETING OF THE REVIEW COMMITTEE ON GENETIC MANIPULATION (RCGM) HELD ON 01.11.2023 IN HYBRID MODE AT INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (ICGEB), NEW DELHI & BY VIDEO CONFERENCING (GO TO MEETING)

The Chairman-RCGM extended a formal welcome to the members of the RCGM for the 270th meeting and initiated the process of the meeting. The list of participants is given at Annexure-I.

2. The Committee adopted the minutes and recommendations of the 269th meeting of the RCGM held on 18.10.2023.

3. On action taken report, the Member-Secretary informed that during the 269th meeting of the RCGM, a total of 25 applications including information items were considered and the Secretariat is in the process of issuing requisite permit letters based on the recommendations of the RCGM.

4. Proposals considered

4.1 Applications in the area of Pharmaceuticals

The Committee considered the applications to receive plasmids and research Cell banks; to import GFP tagged *Bacillus subtilis strains*, transgenic *Drosophila* lines; to conduct preclinical toxicity studies on Pertuzumab Biosimilar; for amendment in approved PCT protocol of Abatacept Biosimilar. After deliberation on each application including information items, appropriate decisions were taken by the RCGM.

4.2 Applications in the area of Agriculture

The Committee considered the applications to transfer and receive seeds of GE maize; reports of Central Compliance Committee on Event Selection Trial of GE Brinjal and GE cotton lines; to conduct Event Selection Trial of GE Chickpea lines; report of BRL-I 1st Year trial of GE maize. After deliberation on each application including information items, appropriate decisions were taken by the RCGM.

5. IBSC Reports

The Committee considered minutes submitted by twenty five IBSCs, fifteen annual compliance reports and nil medical surveillance report, and appropriate decisions were taken by the RCGM.


6. Other items

An interactive session of Biopharma industry stakeholders with RCGM members on the proposed write-up on the waiver of Non-clinical studies requirements in the process of Biosimilar development was conducted.

No other transaction took place and the meeting ended with a vote of thanks to the Chair and members.

The Minutes are approved.

Approved




**(Prof. Y.K. Gupta)
Chairman, RCGM**

Annexure-I

List of Participants:		
1.	Prof. Y.K. Gupta, Former Professor, AIIMS, New Delhi; President AIIMS, Bhopal &, AIIMS, Jammu	Chairman
2.	Dr. Ramesh Sonti, Director & Group Leader, Plant-microbe Interaction, International Centre for Genetic Engineering and Biotechnology, New Delhi	Co-Chair (Agri)
3.	Dr. Arvind Sahu, Executive Director, Regional Centre for Biotechnology, Faridabad (Through VC)	Co-Chair (Biopharma)
4.	Dr. Nitin K. Jain, Scientist 'G' & Head, Regulation, DBT, New Delhi	Member-Secretary
5.	Dr. Neelam S. Sangwan, Professor (Biochemistry), Central University of Haryana, Mahendergarh (Through VC)	Member
6.	Dr. Chandish R. Ballal, Former Director, National Bureau of Agricultural Insect Resources, Bengaluru (Through VC)	Member
7.	Dr. S. N. Sudhakar Babu, Former Head, Crop Production & Principle Scientist (Agronomy), ICAR-Indian Institute of Oil Seed Research, Hyderabad	Member
8.	Dr. Vinay Nandicoori, Director, CSIR-CCMB, Hyderabad (Through VC)	Member
9.	Dr. P. V. Mohanan, Scientist 'G', SCTIMST, Thiruvananthapuram	Member
10.	Dr. K.G. Tirumurugaan, Professor, Department of Animal Biotechnology, Madras Veterinary College, TANUVAS, Chennai	Member
11.	Dr. Ritu Aggarwal, Professor, Post Graduate Institute of Medical Education & Research, Chandigarh (Through VC)	Member
12.	Dr. Asha Chaubey, Sr. Principal Scientist & Head of Fermentation Technology Division, CSIR-IIIM, Jammu (Through VC)	Member
13.	Dr. Rubina Bose, Deputy Drugs Controller (India), CDSCO. Nominee/Representative – CDSCO (Through VC)	
14.	Smt. A. Visala, Deputy Drugs Controller (India), CDSCO. Nominee/Representative – CDSCO (Through VC)	Member
15.	Sh. Rajappan Viswanathan, Astt. Drugs Controller (India), CDSCO. Nominee/Representative – CDSCO	Member
16.	Sh. Naveen Yadav, Drugs Inspector, CDSCO. Nominee/Representative – CDSCO	Member
17.	Dr. Geeta Jotwani, Deputy Director General (Senior Grade) & Scientist F-ICMR. Nominee/Representative – ICMR (Through VC)	Member
18.	Dr. Abhilasha Singh Mathuriya, Scientist D, Ministry of Environment, Forest and Climate Change, Government of India. Nominee/Representative - MoEF&CC	Member
19.	Mr. Sunil Sharma, Ministry of Home Affairs. Nominee/Representative - Ministry of Home Affairs	Member
20.	Mr. Subho Chakraborty, Ministry of Home Affairs. Nominee/Representative - Ministry of Home Affairs	Member
21.	Mr. Gaurav Verma, Ministry of Home Affairs. Nominee/Representative - Ministry of Home Affairs	Member
22.	Dr. Anant Narayan Bhatt, Institute of Nuclear Medicine and Allied Sciences (INMAS). Nominee/Representative - Defense Research and Development Organization (Through VC)	Member

23.	Dr. Gandharva Nagpal, Scientist 'D', DBT, New Delhi	Co-Member Secretary
Department of Biotechnology:		
24.	Dr. Sumita Kumari, Scientist 'D'	
25.	Dr. Lokesh Kumar Narnoliya, Scientist 'D'	
Biosafety Support Unit:		
26.	Dr. Govind Kumar Rai, Scientist & Coordinator	
27.	Dr. Poonam Vishwakarma, Scientist	
28.	Dr. Pranjali Vishwakarma, Scientist	
29.	Dr. Manpreet Kaur, Scientist	
30.	Dr. Shipra Shahi, Scientist	
31.	Dr. Subhasish Dutta, Scientist	
Others/Stakeholders:		
32.	Dr. Sanjeev Kumar, M/s. Zydus Lifesciences Limited, Ahmedabad (Through VC)	
33.	Dr. Samir Sangitrao, M/s. Zydus Lifesciences Limited, Ahmedabad	
34.	Dr. Sanjeev Gupta, M/s. Ipca Laboratories Limited, Mumbai	
35.	Mr. Prasun Guha, M/s. Intas Pharmaceuticals, Ahmedabad (Through VC)	
36.	Ms. Anita Krishnan, M/s. Biocon Biologics, Bengaluru	
37.	Mr. Parag Nagarkar, M/s. Serum Institute of India Pvt. Ltd., Pune	
38.	Mr. Satish Panchal, Sun Pharmaceutical Industries, Vadodara (Through VC)	
39.	Mr. Rustom Mody, Sun Pharmaceutical Industries, Mumbai (Through VC)	

↑

→